Results 11 to 20 of about 633,971 (314)
Designing ecologically optimized pneumococcal vaccines using population genomics. [PDF]
Nat Microbiol, 2020 Colijn C, Corander J, Croucher NJ.
europepmc +2 more sources
Clonal expansion within pneumococcal serotype 6C after use of seven-valent vaccine [PDF]
, 2013 Streptococcus pneumoniae causes invasive infections, primarily at the extremes of life. A seven-valent conjugate vaccine (PCV7) is used to protect against invasive pneumococcal disease in children.
Chan, Jacqueline +10 more
core +28 more sources
Immunogenicity of pneumococcal vaccines in comorbid autoimmune and chronic respiratory diseases [PDF]
Human Vaccines & Immunotherapeutics, 2019 Streptococcus pneumoniae causes pneumonia, meningitis, otitis media, and bacteremia. The mortality and morbidity of invasive pneumococcal disease are high among adults aged >65 years or those with underlying chronic or immunosuppressive conditions.
Koji Kuronuma, Hiroki Takahashi
doaj +2 more sources
Pneumococcal whole-cell and protein-based vaccines: changing the paradigm
Expert Review of Vaccines, 2017 Introduction: Epidemiologic evaluations of Streptococcus pneumoniae nasopharyngeal (NP) colonization and pneumococcal disease suggest that newer serotypes in future formulations of pneumococcal conjugate vaccines (PCVs) are needed and there may need to ...
Michael E. Pichichero
doaj +2 more sources
Systematic review on serotypes distribution of pneumococcal pneumonia in adults and the elderly [PDF]
BMC Public HealthBackground Pneumococcal pneumonia is a major cause of morbidity and mortality among adults, especially those over 65 years of age. Understanding pneumococcal serotype-specific epidemiology in adults and elderly is necessary to inform vaccination policies
Fatiha Mrabt, Sandra Guedes
doaj +2 more sources
Effectiveness of pneumococcal vaccine [PDF]
The Lancet, 1998 L Moulton +2 more
openaire +4 more sources
Journal of Medical Microbiology, 1996 Streptococcus pneumoniae, commonly termed the pneumococcus, is a major pediatric pathogen both in developed and developing countries. Despite the availability of multiple antimicrobials to which this organism is susceptible, it continues to cause significant morbidity and mortality. Recognition of the limitations of antimicrobial therapy in controlling
G, Peter, J O, Klein
openaire +4 more sources
Strengths and weaknesses of pneumococcal conjugate vaccines
Glycoconjugate Journal, 2023 Multivalent vaccines addressing an increasing number of Streptococcus pneumoniae types (7-, 10-, 13-, 15-, 20-valent) have been licensed over the last 22 years.
F. Micoli +4 more
semanticscholar +1 more source
Биопрепараты: Профилактика, диагностика, лечение, 2021 Streptococcus pneumoniae infection is the most common cause of high morbidity and mortality among children under 5 years of age, immunocompromised people, and the elderly.
M. V. Savkina +6 more
doaj +1 more source
Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia
American Journal of Hematology, Volume 98, Issue 1, Page 122-130, January 2023., 2023 Abstract Major options for second‐line therapy in adults with chronic immune thrombocytopenia (ITP) include splenectomy, rituximab, and thrombopoietin receptor agonists (TRAs). The American Society of Hematology guidelines recommend rituximab over splenectomy, TRAs over rituximab, and splenectomy or TRAs while noting a lack of evidence on the cost ...
George Goshua +5 more
wiley +1 more source